Evidence map›Paper›PMID 34339266›Full record

ArticleAntimicrobial agents and chemotherapy2021

Efficacy of Delafloxacin against the Biothreat Pathogen Burkholderia pseudomallei.

Sandra McCurdy, Erin Duffy, Mark Hickman, Stephanie Halasohoris, Steven D Zumbrun

Open access · hybridAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Delafloxacin: what does a new fluoroquinolone offer?Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Sandra McCurdyMelinta Therapeutics, Morristown, New Jersey, USA.ORCID 0000-0003-1702-9072
Erin DuffyMelinta Therapeutics, Morristown, New Jersey, USA.
Mark HickmanJoint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), Joint Product Manager CBRN Medical, Frederick, Maryland, USA.
Stephanie HalasohorisU.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Frederick, Maryland, USA.
Steven D ZumbrunU.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Frederick, Maryland, USA.
Melinta Therapeutics (United States) · USUnited States Army Medical Research Institute of Infectious Diseases · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The

Indexed as

Burkholderia pseudomalleiMelioidosisAnimalsAnti-Bacterial AgentsFluoroquinolonesMiceAnti-Bacterial AgentsdelafloxacinFluoroquinolonesbiothreatBurkholderiadelafloxacinfluoroquinolone

Identifiers

PMID34339266
PMCPMC8448139
OpenAlexW3187993769

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.